Alzheimer’s Disease (AD) is one of the most feared health problems for older Americans a devastating affliction with no cure that progressively steals one’s memory, cognition and identity. It is complicated by the fact that the disease is not fully understood, so diagnosis and treatment can be challenging. For many, this is death before dying.
With a price tag exceeding $300 billion on AD-related treatment and $244 billion in uncompensated care of more than 5 million patients in the U.S. alone, Alzheimer’s Disease can be emotionally and economically overwhelming.
But what if providers had a way to screen patients rapidly, inexpensively and accurately, allowing them to delay disease advancement with a hyper-targeted treatment plan?
Changing expectations on surviving neurodegenerative diseases through a novel precision medicine paradigm CxPM Precision Medicine is built on the principle that Alzheimer’s Disease is a heterogeneous condition. Leveraging proprietary blood-protein technology, CxPM is working to:
Arm primary care physicians with a more effective early-detection screen
Develop companion diagnostics to aid in therapeutic matching for proprietary drugs, repurposed drugs, other disease states that may have adverse effects on AD patients.
Identify patients that will benefit from specific drugs.
Accelerate the development of new therapies for the treatment of AD.